Inclusion Criteria:  ≥ 18 years old Weight ≥ 40 kg Anticipated life expectancy > 3 months prior to lymphodepletion Karnofsky Performance Score ≥ 70% Histologically confirmed diagnosis of AML In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted MRD detected in bone marrow by MFC Negative pregnancy test (females of childbearing potential only) Agree to use effective birth control Left ventricular ejection fraction (LVEF) ≥ 50% Platelet Count ≥ 20 x 109/L Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation) Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation) Hemoglobin ≥ 8.0 g/dL Creatinine Clearance ≥ 40mL/min Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin < 35% of Total Bilirubin) ALT ≤ 2.5 x ULN  Exclusion Criteria:  Cytotoxic chemotherapy within 3 weeks Immune therapy within 4 weeks Immunosuppressive therapy within 2 weeks (with exceptions) Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities Known hypersensitivity to chemotherapy, other agents, or excipients used in this study Female patient that is pregnant or lactating/breastfeeding Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1 (with exceptions) History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents) Active CNS involvement (i.e. leukemic infiltration) Any other malignancy that requires active therapy Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months) Active infection with HIV, Hepatitis B or Hepatitis C  NOTE: other protocol defined inclusion/exclusion criteria may apply.